{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:50:30Z","timestamp":1740124230462,"version":"3.37.3"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fresenius Medical Care Renal Therapies Group"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Despite the growing number of elderly hemodialysis patients, the influence of age on nutritional parameters, serum phosphorus (sP), and use of phosphate-binder (PB) medications has not been well characterized. We aimed to describe age-related differences in patient characteristics in a large, real-world cohort of maintenance hemodialysis patients, and to examine the impact of age on sP management with sucroferric oxyhydroxide (SO).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively analyzed de-identified data from 2017 adult, in-center hemodialysis patients who switched from another PB to SO monotherapy as part of routine clinical care. Changes in baseline PB pill burden, sP levels, and nutritional and dialytic clearance parameters were assessed across varying age groups through 6\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At baseline, older patients had lower mean sP, serum albumin, and pre-dialysis weights compared with younger patients. Prescription of SO was associated with a 62% increase in the proportion of patients achieving sP\u2009\u2264\u20095.5\u00a0mg\/dl and a 42% reduction in daily pill burden. The proportion of patients achieving sP\u2009\u2264\u20095.5\u00a0mg\/dl after transitioning to SO increased by 113, 96, 68, 77, 61, 37 and 40% among those aged 19\u201329, 30\u201339, 40\u201349, 50\u201359, 60\u201369, 70\u201379, and\u2009\u2265\u200980\u00a0years, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Older patients had worse nutritional parameters, lower pill burden, and lower sP at baseline versus younger counterparts. Prescription of SO was associated with improved sP control and reduced pill burden across all ages.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11255-022-03327-w","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T16:49:39Z","timestamp":1660236579000},"page":"377-387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A real-world analysis of the influence of age on maintenance hemodialysis patients: managing serum phosphorus with sucroferric oxyhydroxide as part of routine clinical care"],"prefix":"10.1007","volume":"55","author":[{"given":"Connie M.","family":"Rhee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meijiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael","family":"Woznick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudy","family":"Mullon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Anger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3523-0028","authenticated-orcid":false,"given":"Linda H.","family":"Ficociello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"key":"3327_CR1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41581-020-0315-4","volume":"16","author":"J Himmelfarb","year":"2020","unstructured":"Himmelfarb J, Vanholder R, Mehrotra R, Tonelli M (2020) The current and future landscape of dialysis. Nat Rev Nephrol 16:573\u2013585","journal-title":"Nat Rev Nephrol"},{"key":"3327_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/ckj\/sfz069","volume":"13","author":"A Weigert","year":"2020","unstructured":"Weigert A, Drozdz M, Silva F et al (2020) Influence of gender and age on haemodialysis practices: a European multicentre analysis. Clin Kidney J 13:217\u2013224","journal-title":"Clin Kidney J"},{"key":"3327_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/ckj\/sfz143","volume":"14","author":"X Ye","year":"2021","unstructured":"Ye X, Kooman JP, van der Sande FM et al (2021) Relationship between serum phosphate levels and survival in chronic hemodialysis patients: interactions with age, malnutrition and inflammation. Clin Kidney J 14:348\u2013357","journal-title":"Clin Kidney J"},{"key":"3327_CR4","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1093\/ndt\/14.7.1679","volume":"14","author":"M Aparicio","year":"1999","unstructured":"Aparicio M, Cano N, Chauveau P et al (1999) Nutritional status of haemodialysis patients: a French national cooperative study. French study group for nutrition in dialysis. Nephrol Dial Transplant 14:1679\u20131686","journal-title":"Nephrol Dial Transplant"},{"key":"3327_CR5","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2215\/CJN.03530410","volume":"6","author":"B Canaud","year":"2011","unstructured":"Canaud B, Tong L, Tentori F et al (2011) Clinical practices and outcomes in elderly hemodialysis patients: results from the dialysis outcomes and practice patterns study (DOPPS). Clin J Am Soc Nephrol 6:1651\u20131662","journal-title":"Clin J Am Soc Nephrol"},{"key":"3327_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1053\/j.jrn.2013.01.018","volume":"23","author":"P Lertdumrongluk","year":"2013","unstructured":"Lertdumrongluk P, Rhee CM, Park J et al (2013) Association of serum phosphorus concentration with mortality in elderly and nonelderly hemodialysis patients. J Ren Nutr 23:411\u2013421","journal-title":"J Ren Nutr"},{"key":"3327_CR7","doi-asserted-by":"publisher","first-page":"628","DOI":"10.7150\/ijms.8.628","volume":"8","author":"G \u00c7elik","year":"2011","unstructured":"\u00c7elik G, Oc B, Kara I, Y\u0131lmaz M, Yuceaktas A, Apiliogullari S (2011) Comparison of nutritional parameters among adult and elderly hemodialysis patients. Int J Med Sci 8:628\u2013634","journal-title":"Int J Med Sci"},{"key":"3327_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.xkme.2019.07.005","volume":"1","author":"SS Kalantar","year":"2019","unstructured":"Kalantar SS, You AS, Norris KC et al (2019) The impact of race and ethnicity upon health-related quality of life and mortality in dialysis patients. Kidney Med 1:253\u2013262","journal-title":"Kidney Med"},{"key":"3327_CR9","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1056\/NEJMoa0904655","volume":"361","author":"M Kurella Tamura","year":"2009","unstructured":"Kurella Tamura M, Covinsky KE, Chertow GM, Yaffe K, Landefeld CS, McCulloch CE (2009) Functional status of elderly adults before and after initiation of dialysis. N Engl J Med 361:1539\u20131547","journal-title":"N Engl J Med"},{"key":"3327_CR10","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1159\/000509309","volume":"51","author":"A Ishiwatari","year":"2020","unstructured":"Ishiwatari A, Yamamoto S, Fukuma S, Hasegawa T, Wakai S, Nangaku M (2020) Changes in quality of life in older hemodialysis patients: a cohort study on dialysis outcomes and practice patterns. Am J Nephrol 51:650\u2013658","journal-title":"Am J Nephrol"},{"key":"3327_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1681\/ASN.2012010047","volume":"24","author":"JC Kim","year":"2013","unstructured":"Kim JC, Kalantar-Zadeh K, Kopple JD (2013) Frailty and protein-energy wasting in elderly patients with end stage kidney disease. J Am Soc Nephrol 24:337\u2013351","journal-title":"J Am Soc Nephrol"},{"key":"3327_CR12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s40620-019-00689-w","volume":"33","author":"J Floege","year":"2020","unstructured":"Floege J (2020) Phosphate binders in chronic kidney disease: an updated narrative review of recent data. J Nephrol 33:497\u2013508","journal-title":"J Nephrol"},{"key":"3327_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1681\/ASN.2021010027","volume":"32","author":"R Wald","year":"2021","unstructured":"Wald R, Walsh MW (2021) In search of the optimal target for phosphate control: episode 1. J Am Soc Nephrol 32:526\u2013528","journal-title":"J Am Soc Nephrol"},{"key":"3327_CR14","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.1161\/01.RES.87.7.e10","volume":"87","author":"S Jono","year":"2000","unstructured":"Jono S, McKee MD, Murry CE et al (2000) Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87:E10\u2013E17","journal-title":"Circ Res"},{"key":"3327_CR15","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1253\/circj.CJ-14-0735","volume":"78","author":"P Gross","year":"2014","unstructured":"Gross P, Six I, Kamel S, Massy ZA (2014) Vascular toxicity of phosphate in chronic kidney disease: beyond vascular calcification. Circ J 78:2339\u20132346","journal-title":"Circ J"},{"key":"3327_CR16","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208\u20132218","journal-title":"J Am Soc Nephrol"},{"key":"3327_CR17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","volume":"52","author":"F Tentori","year":"2008","unstructured":"Tentori F, Blayney MJ, Albert JM et al (2008) Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 52:519\u2013530","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"3327_CR18","first-page":"1","volume":"2017","author":"Kidney, Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2011","unstructured":"Kidney, Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group (2011) Prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2017(7):1\u201359","journal-title":"Kidney Int Suppl"},{"key":"3327_CR19","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1093\/ndt\/gft244","volume":"28","author":"AA Waheed","year":"2013","unstructured":"Waheed AA, Pedraza F, Lenz O, Isakova T (2013) Phosphate control in end-stage renal disease: barriers and opportunities. Nephrol Dial Transplant 28:2961\u20132968","journal-title":"Nephrol Dial Transplant"},{"key":"3327_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ekir.2017.10.003","volume":"3","author":"F Koiwa","year":"2018","unstructured":"Koiwa F, Yokoyama K, Fukagawa M, Akizawa T (2018) Efficacy and safety of sucroferric oxyhydroxide and calcium carbonate in hemodialysis patients. Kidney Int Rep 3:185\u2013192","journal-title":"Kidney Int Rep"},{"unstructured":"US-DOPPS (Dialysis Outcomes and Practice Patterns Study) practice monitor: phosphate binder use, last 3 months. 2020. Available at https:\/\/www.dopps.org\/dpm\/DPMSlideBrowser.aspx?type=Topic&id=11. Accessed Apr 2, 2021.","key":"3327_CR21"},{"unstructured":"US-DOPPS (Dialysis Outcomes and Practice Patterns Study) practice monitor. Serum phosphorus (most recent). https:\/\/www.dopps.org\/DPM\/. Accessed Apr 2, 2021.","key":"3327_CR22"},{"key":"3327_CR23","first-page":"525","volume":"23","author":"MD Arenas","year":"2010","unstructured":"Arenas MD, Malek T, Gil MT, Moledous A, Alvarez-Ude F, Reig-Ferrer A (2010) Challenge of phosphorus control in hemodialysis patients: a problem of adherence. J Nephrol 23:525\u2013534","journal-title":"J Nephrol"},{"key":"3327_CR24","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2215\/CJN.00290109","volume":"4","author":"YW Chiu","year":"2009","unstructured":"Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R (2009) Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol 4:1089\u20131096","journal-title":"Clin J Am Soc Nephrol"},{"key":"3327_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/hdi.12315","volume":"20","author":"RB Fissell","year":"2016","unstructured":"Fissell RB, Karaboyas A, Bieber BA et al (2016) Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: findings from the DOPPS. Hemodial Int 20:38\u201349","journal-title":"Hemodial Int"},{"key":"3327_CR26","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1093\/ndt\/gft280","volume":"29","author":"S Wang","year":"2014","unstructured":"Wang S, Alfieri T, Ramakrishnan K, Braunhofer P, Newsome BA (2014) Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis. Nephrol Dial Transplant 29:2092\u20132099","journal-title":"Nephrol Dial Transplant"},{"key":"3327_CR27","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/ki.2014.58","volume":"86","author":"J Floege","year":"2014","unstructured":"Floege J, Covic AC, Ketteler M et al (2014) A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int 86:638\u2013647","journal-title":"Kidney Int"},{"key":"3327_CR28","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/ndt\/gfv006","volume":"30","author":"J Floege","year":"2015","unstructured":"Floege J, Covic AC, Ketteler M et al (2015) Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant 30:1037\u20131046","journal-title":"Nephrol Dial Transplant"},{"key":"3327_CR29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.5414\/CN109021","volume":"88","author":"DW Coyne","year":"2017","unstructured":"Coyne DW, Ficociello LH, Parameswaran V et al (2017) Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data. Clin Nephrol 88:59\u201367","journal-title":"Clin Nephrol"},{"key":"3327_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000487856","volume":"47","author":"K Kalantar-Zadeh","year":"2018","unstructured":"Kalantar-Zadeh K, Parameswaran V, Ficociello LH et al (2018) Real-world scenario improvements in serum phosphorus levels and pill burden in peritoneal dialysis patients treated wtih sucroferric oxyhydroxide. Am J Nephrol 47:153\u2013161","journal-title":"Am J Nephrol"},{"key":"3327_CR31","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1053\/j.jrn.2018.11.002","volume":"29","author":"J Kendrick","year":"2019","unstructured":"Kendrick J, Parameswaran V, Ficociello LH et al (2019) One-year historical cohort study of the phosphate binder sucroferric oxyhydroxide in patients on maintenance hemodialysis. J Renal Nutr 29:428\u2013437","journal-title":"J Renal Nutr"},{"key":"3327_CR32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.xkme.2020.01.009","volume":"2","author":"DW Coyne","year":"2020","unstructured":"Coyne DW, Ficociello LH, Parameswaran V et al (2020) Sucroferric oxyhydroxide in maintenance hemodialysis: a retrospective, comparative cohort study. Kidney Med 2:307\u2013316","journal-title":"Kidney Med"},{"key":"3327_CR33","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD CKDC","year":"2020","unstructured":"GBD CKDC (2020) Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet 395:709\u2013733","journal-title":"Lancet"},{"key":"3327_CR34","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1053\/ajkd.2001.24532","volume":"37","author":"V Lorenzo","year":"2001","unstructured":"Lorenzo V, Mart\u00edn M, Rufino M et al (2001) Protein intake, control of serum phosphorus, and relatively low levels of parathyroid hormone in elderly hemodialysis patients. Am J Kidney Dis 37:1260\u20131266","journal-title":"Am J Kidney Dis"},{"key":"3327_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185853","volume":"12","author":"JE Lee","year":"2017","unstructured":"Lee JE, Lim JH, Jang HM et al (2017) Low serum phosphate as an independent predictor of increased infection-related mortality in dialysis patients: a prospective multicenter cohort study. PLoS ONE 12:e0185853","journal-title":"PLoS ONE"},{"key":"3327_CR36","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1053\/j.ajkd.2005.12.039","volume":"47","author":"AK Pieper","year":"2006","unstructured":"Pieper AK, Haffner D, Hoppe B et al (2006) A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD. Am J Kidney Dis 47:625\u2013635","journal-title":"Am J Kidney Dis"},{"key":"3327_CR37","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0022-3476(86)81064-2","volume":"108","author":"IB Salusky","year":"1986","unstructured":"Salusky IB, Coburn JW, Foley J, Nelson P, Fine RN (1986) Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis. J Pediatr 108:767\u2013770","journal-title":"J Pediatr"},{"key":"3327_CR38","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00467-017-3787-0","volume":"33","author":"S Fathallah-Shaykh","year":"2018","unstructured":"Fathallah-Shaykh S, Drozdz D, Flynn J et al (2018) Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease. Pediatr Nephrol 33:325\u2013333","journal-title":"Pediatr Nephrol"},{"key":"3327_CR39","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00467-020-04805-y","volume":"36","author":"LA Greenbaum","year":"2021","unstructured":"Greenbaum LA, Jeck N, Klaus G et al (2021) Safety and efficacy of sucroferric oxyhydroxide in pediatric patients with chronic kidney disease. Pediatr Nephrol 36:1233\u20131244","journal-title":"Pediatr Nephrol"},{"key":"3327_CR40","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s00223-020-00665-8","volume":"108","author":"J Bacchetta","year":"2021","unstructured":"Bacchetta J, Bernardor J, Garnier C, Naud C, Ranchin B (2021) Hyperphosphatemia and chronic kidney disease: a major daily concern both in adults and in children. Calcif Tissue Int 108:116\u2013127","journal-title":"Calcif Tissue Int"},{"key":"3327_CR41","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1007\/s00467-014-3017-y","volume":"30","author":"L Rees","year":"2015","unstructured":"Rees L, Shroff R (2015) The demise of calcium-based phosphate binders-is this appropriate for children. Pediatr Nephrol 30:2061\u20132071","journal-title":"Pediatr Nephrol"},{"key":"3327_CR42","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00467-009-1328-1","volume":"25","author":"E Gonzalez","year":"2010","unstructured":"Gonzalez E, Schomberg J, Amin N, Salusky IB, Zaritsky J (2010) Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients. Pediatr Nephrol 25:373\u2013375","journal-title":"Pediatr Nephrol"},{"key":"3327_CR43","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s11914-017-0365-0","volume":"15","author":"MR Hanudel","year":"2017","unstructured":"Hanudel MR, Salusky IB (2017) Treatment of pediatric chronic kidney disease\u2013mineral and bone disorder. Curr Osteoporos Rep 15:198\u2013206","journal-title":"Curr Osteoporos Rep"},{"key":"3327_CR44","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1053\/j.jrn.2017.02.007","volume":"27","author":"F Koiwa","year":"2017","unstructured":"Koiwa F, Yokoyama K, Fukagawa M, Akizawa T (2017) Long-term assessment of the safety and efficacy of PA21 (sucroferric oxyhydroxide) in Japanese hemodialysis patients with hyperphosphatemia: an open-lable, multicenter, phase III study. J Ren Nutr 27:346\u2013354","journal-title":"J Ren Nutr"},{"key":"3327_CR45","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s12882-019-1582-9","volume":"20","author":"K Kalantar-Zadeh","year":"2019","unstructured":"Kalantar-Zadeh K, Ficociello LH, Parameswaran V et al (2019) Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study. BMC Nephrol 20:396","journal-title":"BMC Nephrol"},{"key":"3327_CR46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1053\/j.ajkd.2014.01.429","volume":"64","author":"D Fouque","year":"2014","unstructured":"Fouque D, Horne R, Cozzolino M, Kalantar-Zadeh K (2014) Balancing nutrition and serum phosphorus in maintenance dialysis. Am J Kidney Dis 64:143\u2013150","journal-title":"Am J Kidney Dis"},{"key":"3327_CR47","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2369-9-2","volume":"9","author":"C Karamanidou","year":"2008","unstructured":"Karamanidou C, Clatworthy J, Weinman J, Horne R (2008) A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol 9:2","journal-title":"BMC Nephrol"},{"key":"3327_CR48","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/1471-2369-14-208","volume":"14","author":"MT Martins","year":"2013","unstructured":"Martins MT, Silva LF, Kraychete A et al (2013) Potentially modifiable factors associated with non-adherence to phosphate binder use in patients on hemodialysis. BMC Nephrol 14:208","journal-title":"BMC Nephrol"},{"key":"3327_CR49","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2147\/PPA.S145648","volume":"12","author":"EM Umeukeje","year":"2018","unstructured":"Umeukeje EM, Mixon AS, Cavanaugh KL (2018) Phosphate-control adherence in hemodialysis patients: current perspectives. Patient Pref Adher 12:1175\u20131191","journal-title":"Patient Pref Adher"},{"key":"3327_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144119","volume":"10","author":"S Ghimire","year":"2015","unstructured":"Ghimire S, Castelino RL, Lioufas NM, Peterson GM, Zaidi STR (2015) Nonadherence to medication therapy in haemodialysis paitents: a systematic review. PLoS ONE 10:e0144119","journal-title":"PLoS ONE"},{"key":"3327_CR51","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/sj.ki.5002059","volume":"71","author":"GA Block","year":"2007","unstructured":"Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM (2007) Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71:438\u2013441","journal-title":"Kidney Int"},{"key":"3327_CR52","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1681\/ASN.2008060609","volume":"20","author":"T Isakova","year":"2009","unstructured":"Isakova T, Guti\u00e9rrez OM, Chang Y et al (2009) Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 20:388\u2013396","journal-title":"J Am Soc Nephrol"},{"key":"3327_CR53","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1053\/j.ajkd.2011.12.025","volume":"60","author":"AA Lopes","year":"2012","unstructured":"Lopes AA, Tong L, Thumma J et al (2012) Phosphate binder use and mortality among hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 60:90\u2013101","journal-title":"Am J Kidney Dis"},{"key":"3327_CR54","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1681\/ASN.2020050598","volume":"32","author":"Y Isaka","year":"2021","unstructured":"Isaka Y, Hamano T, Fujii H et al (2021) Optimal phosphate control related to coronary artery calcification in dialysis patients. J Am Soc Nephrol 32:723\u2013735","journal-title":"J Am Soc Nephrol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03327-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-022-03327-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03327-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T03:38:19Z","timestamp":1674272299000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-022-03327-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":54,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["3327"],"URL":"https:\/\/doi.org\/10.1007\/s11255-022-03327-w","relation":{},"ISSN":["1573-2584"],"issn-type":[{"type":"electronic","value":"1573-2584"}],"subject":[],"published":{"date-parts":[[2022,8,11]]},"assertion":[{"value":"19 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MZ, RW, CM, MSA, and LHF are employees of Fresenius Medical Care. CM and MSA\u00a0own stock in Fresenius Medical Care AG & Co. KGaA. CMR has received honoraria and\/or support from Ardelyx, AstraZeneca, Dexcom Inc., Fresenius, Nutricia, Reata, and Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"There was no recruitment of subjects in this study. It was a retrospective database analysis using de-identified existing data records. This study was reviewed by New England Independent Review Board (NEIRB) and determined to be exempted under the Common Rule and applicable guidance (NEIRB Work Order #: 1\u201310085-1; Sponsor Protocol #: EBM 2019 003). We adhered to the Declaration of Helsinki; informed consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}}]}}